Impact of Annual Exposure to Polycyclic Aromatic Hydrocarbons on Acute Exacerbation Frequency in Asthmatic Patients.

PURPOSE: Exposure to polycyclic aromatic hydrocarbons (PAHs) associated with ambient air particulate matter (PM) poses significant health concerns. Increased acute exacerbation (AE) frequency in asthmatic patients has been associated with ambient PAHs, but which subgroup of patients are particularly susceptible to ambient PAHs is uncertain. We developed a new model to simulate grid-scale PM2.5-PAH levels in order to evaluate whether the severity of asthma as measured by the Global Initiative of Asthma (GINA) levels of treatment is related to cumulative exposure of ambient PAHs.
METHODS: Patients with asthma residing in the northern Taiwan were reviewed retrospectively from 2014 to 2017. PM2.5 were sampled and analysed for PAHs twice a month over a 72-hour period, in addition to collecting the routinely monitored air pollutant data from an established air quality monitoring network. In combination with correlation analysis and principal component analysis, multivariate linear regression models were performed to simulate hourly grid-scale PM2.5-PAH concentrations (ng/m3). A geographic information system mapping approach with ordinary kriging interpolation method was used to calculate the annual exposure of PAHs (ng/m).
RESULTS: Among the 387 patients with asthma aged 18 to 93 (median 62), 97 subjects were treated as GINA step 5 (24%). Asthmatics in GINA 5 subgroup with high annual PAHs exposure were likely to have a higher annual frequency of any AE (1 (0-12), p<0.0001). Annual PAHs exposure was correlated with the annual frequency of any exacerbation (r=0.11, p=0.02). This was more significant in the GINA 5 subgroup (r=0.29, p=0.005) and in the GINA 5 subgroup with severe acute exacerbations (r=0.51, p=0.002). Annual PAHs exposure, severe acute exacerbation and GINA steps were independent variables that predict annual frequency of any exacerbation.
CONCLUSION: Asthmatic patients in the GINA 5 subgroup with acute exacerbations were more susceptible to the effect of environmental PAHs on their exacerbation frequency. Reducing environmental levels of PAHs will have the greatest impact on the more severe asthma patients.

Introduction

Exposure to polycyclic aromatic hydrocarbons (PAHs) associated with ambient air particulate matter (PM) poses significant health concerns.1,2 According to the World Health Organization (WHO) ambient air pollution database, it is the fifth leading risk factor for mortality worldwide and continues to be a global problem affecting people in urban areas.3 Polycyclic aromatic hydrocarbons, mainly from incomplete combustion of fossil fuels and coals,4 can bind to particulate matter to enter into the human body through the respiratory system,5 and accumulate in the tracheobronchial and alveolar epithelium, through which they can enter the circulatory system.6,7 PAHs may cause oxidative injury to the airways, leading to inflammation, remodeling, and an increased risk of allergic sensitization;8–10 in addition, they may increase the incidence and worsen pulmonary diseases such as chronic pulmonary obstructive lung disease,11 lung cancer,12 and asthma.13,14

Asthma, a common chronic inflammatory airways disease, is characterized by airway hyperresponsiveness,15 and is particularly susceptible to ambient air pollutants which have been associated with an increase in acute exacerbation frequency. Exposure to traffic-related air pollutants such as fine particulate matter of 2.5 μm or less in diameter (PM2.5) during childhood also may favor the development of asthma as well as having a deleterious effect on the asthmatic state in children.16 Acute exacerbations needing emergency room visits17–19 and hospital admissions20,21 are increased in asthmatic patients following high levels of ambient air pollutant. Exposure to PAHs, which is a major component of fine particulate matter of air pollution, may induce oxidative stress and airway inflammation, and increase asthma exacerbations.22–24 Although the link between ambient air pollutants and asthma exacerbations has been highlighted, it is not known which subgroup of asthmatic patients are particularly affected by long-term exposure to PAHs. Asthma disease severity based on Global initiative of asthma (GINA) step treatment has been associated with an increasing rate of acute exacerbations.25 Therefore, the objective of our study was to evaluate whether the severity of asthma as measured by the GINA level of treatment needed is related to the long-term cumulative exposure of yearly ambient levels of PAHs. We used a recently developed grid-scale model to simulate the hourly spatiotemporal distribution of PM2.5-PAHs and to derive an annual cumulative exposure to PAHs.26 We hypothesized that increasing annual cumulative exposure to PAHs would be associated with a greater frequency of any acute exacerbations in the more severe patients with asthma.

Methods

Study Subjects

From January 2014 to December 2017, 477 patients who fulfilled the criteria of American Thoracic Society (ATS) for asthma at Chang Gung Memorial Hospital (CGMH) and Taoyuan General Hospital, Ministry of Health and Welfare (TYGH),27 were retrospectively reviewed. Inclusion criteria were (1) ≥ 18-years of age (2) receiving regular treatment of anti-asthma medication for more than 1 year (3) a record of reversibility of forced expiration volume in the first second (FEV1) (an increase in FEV1 of ≥ 12% and 200 mL spontaneously after inhaled short-acting β2 agonists) and (4) the patients lived in Taoyuan city, Taipei city, or New Taipei city in Taiwan. Patients with the following diseases, such as malignancy, bronchiectasis, chronic obstructive pulmonary disease, active respiratory inflammatory of infectious diseases (pulmonary tuberculosis or pneumonia), connective tissue diseases, unstable cardiovascular diseases (coronary artery disease, congestive heart disease, etc.) and active major systemic diseases (liver, renal, metabolism, etc.) were excluded. Asthma treatment was classified according to GINA 2017 treatment steps,28 as follows: Treatment step1: As needed inhaled short-acting beta2 agonist (SABA). Treatment step2: Regular inhaled corticosteroids (ICS) plus as-need SABA. Treatment step3: Maintenance low dose of ICS with LABA plus as-need SABA. Treatment step4: Maintenance medium to high dose ICS with LABA plus as-need SABA. Treatment step5: Maintenance medium to high dose ICS with LABA, and/or add-on long-acting anticholinergic antagonist (LAMA) or anti-IgE, and/or oral corticosteroids (OCS) maintenance or as-needed. Compliance to medication was also recorded. Twenty-three patients were excluded because they did not live in the aforementioned areas. Sixty-seven patients were excluded because they were not under regular asthmatic medicine control for more than one year. The remaining 387 patients were eligible for the analysis (Figure 1). The Institution Review Board of Chang Gung Memorial Hospital approved the study according with the Declaration of Helsinki (IRB Number: 201601021B0). The IRB determined that written informed consent was waived due to the retrospective nature of this study, along with no modifications in patient management. All personal information was encrypted in the database, and patient data access was de-identified.

Figure 1

Flow chart of the enrolled patients.

Subgroup Definition

The home address, clinical profiles, allergic status, severity of asthma based on GINA guidelines, and severity and frequency of acute exacerbation were recorded. Atopic status was assessed by an automated immunoassay testing by ImmunoCAP (Phadia Laboratory Systems, Uppsala, Sweden) for total IgE (KU/L) and specific IgE antibodies to common allergens (house dust mite mix, grass mix, mold mix, animal epithelia mix). Positive atopic status was defined as any positive ImmunoCAP test for allergen‐specific IgE (>0.35 KU/L).29,30 Mild acute exacerbation was defined as increased usage of inhaled corticosteroids without moderate or severe exacerbation. Moderate acute exacerbation was defined as needing oral steroids or antibiotics when assessed in the clinic. Severe acute exacerbation includes an event when the patient had to visit the emergency department or has been hospitalized due to respiratory distress.31 The index of acute exacerbation severity was scored as one in patients experiencing a severe acute exacerbation; otherwise, the index was zero. Patients were grouped by GINA step 1 to step 5 according to the GINA guidelines of 2017.28

A Grid-Scale Model for Simulating Hourly PM2.5-PAH Concentrations

To build the hourly PM2.5-PAH grid-scale model, the dataset was collected from 2014 to 2017 in Taipei city, New Taipei city and Taoyuan city and treated with multivariate linear regression (MLR) model for PM2.5-PAH concentration simulation and a geographic information system (GIS) mapping approach with ordinary kriging (OK) interpolation method. Detailed information of the model simulation method has been previously reported.26,32 Briefly, the 72-hour particle samples were collected by a portable air sampler twice a month at six sampling sites (as shown in Figure 2) and the routinely monitored air pollutant data/meteorological data (eg, CO, PM2.5, PM10, NOx, wind speed, relative humidity and ambient temperature) were collected from Taiwan Environmental Protection Administration (TEPA) monitoring stations nearby. After extracting and analysing the PAHs concentration by GC-MS, we applied correlation analysis, principal component analysis (PCA), and stepwise regression approach to determine the predominant sources (eg, vehicle emissions or coal/wood combustion) and predictors of PAHs concentration. Using these datasets and predictors including ambient temperature, CO, NOx, and PM10, an hourly grid-scale model was constructed by MLR for simulation of PM2.5-PAH concentration. Then, a GIS mapping approach with OK interpolation method was used to estimate the hourly PM2.5-PAH concentration of the patient cases and illustrate the spatial variation of PM2.5-PAHs concentrations. The hourly grid-scale model was then applied to calculate each patient’s yearly cumulative PAH exposure at his/her home address.

Figure 2

Sampling sites that were located nearby Taiwan Environmental Protection Administration (TEPA) monitoring stations.

Statistical Analysis

We used Mann–Whitney and Kruskal–Wallis analysis to determine the statistical significance of differences between groups, and Wilcoxon matched-paired test was used to determine within-group differences. Fisher’s exact tests were used to determine the significance differences between groups in terms of gender and smoking status. Pearson’s correlation was used to examine the correlation and multivariable regression analysis was used to determine the independent parameters that predict annual exacerbation frequency. At each step, variables with a significant relationship with annual exacerbation frequency (defined as p≤0.05) were considered for adding to or removing from the set of explanatory variables following a sequence of F-tests (addition if p<0.05 and removal if p>0.10) in multivariable regression analysis by stepwise method. Normally distributed values were expressed as mean ± SE, whereas medians and ranges were used to describe skewed distributed data. All reported P values were two-sided, with p< 0.05 considered statically significant. All data were analyzed using R version 3.5.2 (R foundation for statistical computing)

Results

Baseline Characteristics of Subjects

The 387 patients with asthma include 207 male (53.4%) and 90 smokers or ex-smokers (23.3%). Two hundred and forty-one (63.3%) patients were atopic. Those who experienced asthma exacerbations included 166 (42.9%) no/mild, 89 (23.0%) moderate and 132 (34.1%) severe acute exacerbations from 2014 to 2017, respectively. Current treatment of asthma included 6 (1.6%) GINA step1, 29 (7.5%) GINA step2, 37 (9.6%) GINA step3, 222 (57.4%) GINA step4, and 93 (24%) GINA step5. The median annual frequency of any acute exacerbation was 0.3 (0–12) (time/year) and the annual PAHs concentration was 1.1 (0.7–2.4) (ng/m3/year) (Table 1).

Table 1

Clinical Characteristics of All Asthma Participants

Variables	Total (n =387)
Age, years	62 (18–93)
Gender, male (n, %)	207 (53.4)
Current/ever smokers (n, %)	90 (23.3)
BMI (kg/m2)	24.6 (16.6–38.1)
Atopic (n, %)	241 (63.3)
IgE level (IU/mL)	111 (0–5000)
Non-compliance of medication, (n, %)	116 (34.1)
Pulmonary function test
FVC (L)	2.2 (0.4–5.1)
FVC (% predicted)	76 (15–61)
FEV1 (L)	1.5 (0.3–4.2)
FEV1 (%predicted)	69 (17–156)
FEV1/FVC ratio (%)	71.1 (24–100)
Annual change of FEV1 (%)	−0.7 (−42.0~53.4)
GINA subgroup
GINA 1 (n, %)	6 (1.6)
GINA 2 (n, %)	29 (7.5)
GINA 3 (n, %)	37 (9.6)
GINA 4 (n, %)	222 (57.4)
GINA 5 (n, %)	93 (24.0)
Anti-IgE therapy (n, %)	30 (7.8)
ICS+LABA+LAMA (n, %)	24 (6.2)
Theophylline (n, %)	38 (9.8)
Severity of acute exacerbation
No/mild (n, %)	166 (42.9)
Moderate (n, %)	89 (23.0)
Severe (n, %)	132 (34.1)
Annual frequency of acute exacerbation (time/year)	0.3 (0–12)
Polycyclic aromatic hydrocarbons (ng/m3/year)	1.1 (0.7–2.4)

Note: Data expressed as median and range.

Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting beta2 agonist; IgE, immunoglobulin E; LAMA, long-acting anticholinergic antagonist.

Clinical Characteristics of GINA Step Treatment Subgroups

Patients with asthma in GINA step5 treatment were older, predominantly male, had a greater smoking history, associated with lower pulmonary function, and experienced more severe acute exacerbations as well as a higher annual any exacerbation frequency compared to the other GINA subgroups (Table 2). Otherwise, there was no significant difference of BMI, atopic status, IgE level, the proportion of non-compliance and annual exposure of PAHs (ng/m3/year) between these GINA subgroups (Table 2).

Table 2

Clinical Characteristics of Asthmatic Patients Based on GINA Step Treatment Subgroups

Variables	GINA 1n = 6	GINA 2n = 29	GINA 3n = 37	GINA 4n = 222	GINA 5n = 93	p-value
Age, years	50.5 (30–63)	49 (18–93)	52.5(18–85)	62 (19–93)	64 (28–92)	0.004
Gender, male (n, %)	2 (33.3)	12 (41.4)	16 (43.2)	116 (52.3)	61 (65.6)	0.04
Current/ever smokers (n, %)	5 (83.3)	4 (13.8)	7 (18.9)	45 (20.3)	29 (31.2)	0.003
BMI (Kg/m2)	25.7 (21.0–28.7)	23.6 (18.1–34.4)	24.4 (18.3–37.8)	24.8 (17.5–38.1)	24.3 (16.6–37.7)	0.35
Atopic (n, %)	2 (33.3)	23 (82.1)	23 (62.2)	134 (61.5)	59 (64.1)	0.14
IgE level (IU/mL)	70.6 (2.7–1001)	155 (0–3085.9)	85.9 (2–5000)	99.4 (0–3085.9)	125.5 (2–5000)	0.5
Non-compliance of medication (n, %)	4 (66.7)	11 (37.9)	12 (32.4)	69 (31.1)	20 (21.5)	0.08
Pulmonary function test
FVC (L)	2.6 (2.4–3.4)	2.7 (0.5–4.7)	2.4 (1.2–5.1)	2.1 (0.4–5.0)	2.1 (0.5–4.9)	0.0008
FVC (% predicted)	85 (75–108)	84 (40–122)	86 (44–125)	75 (15–161)	72 (19–134)	0.002
FEV1 (L)	2.1 (1.6–2.3)	2.1 (0.4–4.0)	1.8 (0.5–3.1)	1.5 (0.4–4.2)	1.3 (0.3–3.6)	<0.0001
FEV1 (%predicted)	78.5 (67–94)	78 (49–118)	74 (25–108)	70 (22–156)	55 (17–123)	<0.0001
FEV1/FVC ratio (%)	75.9 (63–85)	78.9 (59–64.6)	73.2 (40.6–99)	73.7 (35.2–100)	63.8 (24.0–91.2)	<0.0001
Frequency of any acute exacerbation (times/year)	0.5 (0–3)	0 (0–3.3)	0 (0–3)	0.3 (0–4.5)	1 (0–12)	<0.0001
Acute exacerbation severity
Non-severe acute exacerbation (n, %)	5 (83.3)	21 (72.4)	28 (75.7)	157 (71.3)	44 (47.3)
Severe acute exacerbation (n, %)	1 (16.7)	8 (27.6)	9 (24.3)	65 (29.3)	49 (52.7)
Polycyclic aromatic hydrocarbons (ng/m3/year)	1.3 (1.0–1.4)	1.1 (0.9–1.6)	1.1 (0.9–1.6)	1.1 (0.7–2.4)	1 (0.9–1.7)	0.42

Note: Data expressed as median and range.

Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity.

Associations Between Clinical Parameters and Annual Acute Exacerbation Frequency or Annual Exposure of PAHs

There was a significant positive correlation between annual concentration of PAHs and the annual frequency of any acute exacerbation (r = 0.11, p = 0.02) (Figure 3). In clinical parameters, the annual frequency of any acute exacerbation was highly correlated with the annual exposure concentration of PAHs, GINA step treatment subgroups, and the acute exacerbation severity (Table 3). The covariates with a significant relationship with annual exacerbation frequency were included for multivariable regression analysis. We found that the annual cumulative exposure of PAHs, GINA step treatment and the severity of exacerbation were the independent variables to predict annual exacerbation frequency (r2=0.42, p<0.0001) (Table 4).

Figure 3

Scatterplot of the annual exposure concentration of polycyclic aromatic hydrocarbons (ng/m3/year) against the annual frequency of any acute exacerbation in asthmatic patients (time/year).

Table 3

Correlations of Clinical Parameters and Annual Frequency of Any Acute Exacerbation

Variables	r value	p value
Age	0.14	0.07
Gender (male vs female)	0.03	0.61
BMI (kg/m2)	0.02	0.71
Smoking (current/ever smokers vs non-smokers)	0.001	0.98
Allergy (atopic vs non-atopic)	−0.02	0.08
Baseline IgE level	0.01	0.78
Compliance (non-compliance vs compliance)	0.06	0.23
GINA step1-5	0.21	<0.0001
Acute exacerbation severity (severe vs non-severe)	0.64	<0.0001
Polycyclic aromatic hydrocarbons (ng/m3/year)	0.11	0.02

Abbreviations: BMI, body mass index; GINA, Global Initiative of Asthma.

Table 4

Multivariable Regression Model for Annual Frequency of Any Acute Exacerbation

Variables	Beta	SE	t value	p value
Polycyclic aromatic hydrocarbons (PAHs, ng/m3/year)	0.69	0.23	2.93	0.004
Acute exacerbation severity	1.67	0.11	15.54	<0.0001
GINA step treatment subgroups	0.16	0.06	2.69	0.007

Notes: r2= 0.42 adjusted r2 = 0.42, Residual standard error = 0.99, p<0.0001.

Abbreviation: SE, standard error of beta.

Relationship Between Annual Frequency of Acute Exacerbation and Annual Exposure Concentration of PAHs in GINA 5 Subgroup

The annual exposure to PAHs was highly correlated with the annual frequency of any exacerbation in the GINA 5 subgroup (R = 0.29 and p = 0.005) (Figure 4A). The correlation of the annual exposure concentration of PAHs and the annual frequency of severe acute exacerbation was more significant in patients who were in GINA step5 subgroup (r=0.51, p=0.002) (Figure 4B). However, there was no association between the annual exposure concentration of PAHs and the annual frequency of non-severe acute exacerbation in asthmatic patients with GINA step5 treatment (Figure 4C). Otherwise, the annual exposure concentration of PAHs against the annual frequency of any/severe/non-severe acute exacerbation showed no significant correlations in asthmatic patients with GINA step 1 to 4 subgroups, respectively (See ).

Figure 4

(A) Scatterplot of the annual exposure concentration of polycyclic aromatic hydrocarbons (ng/m3/year) against the annual frequency of any acute exacerbation (time/year) in asthmatic patients who were in GINA 5 subgroup. (B) Scatterplot of the annual exposure concentration of polycyclic aromatic hydrocarbons (ng/m3/year) against the annual frequency of severe acute exacerbation in asthmatic patients (time/year) who were in GINA 5 subgroup (C) Scatterplot of the annual concentration of polycyclic aromatic hydrocarbons (ng/m3/year) against the annual frequency of any non-severe acute exacerbation (time/year) in asthmatic patients who were in GINA 5 subgroup. P value is indicated.

Discussion

We demonstrated that the annual exposure concentration of PAHs, GINA step treatment subgroups and acute exacerbation severity were independent variables that were highly correlated with the annual frequency of any exacerbation. Based on the GINA step treatment, the more severe group of GINA step 5 asthmatic patients were older, with decreased lung function, higher annual frequency of any acute exacerbation, and with more severe acute exacerbations. Using the grid-scale model for simulating hourly PM2.5-PAH concentrations, we determined the annual exposure concentration of PAHs in these patients with asthma. We found that the annual exposure concentration of PAHs was correlated to the annual frequency of severe acute exacerbation in the patients with asthma in GINA 5 subgroup. However, the association of the annual exposure concentration of PAHs and the annual frequency of non-severe acute exacerbation was not observed in those of GINA 5 asthmatic patients.

Correlation of disease severity according to GINA strategy among higher annual frequency of any exacerbation has been confirmed.25 Our results are compatible with a previous study of more than 200,000 asthmatic patients in the US and UK that reported the annual exacerbation frequency in GINA step5 subgroup as nearly 3-fold higher than the other subgroups.23 Even for those groups exposed to similar concentration of PAHs, there was also a greater correlation between the annual acute exacerbation frequency and the annual exposure concentration of PAHs in the more severe GINA step5 subgroup. Our study is the first report to evaluate the impact of ambient PAHs on different GINA subgroups used as a measure of asthma severity and suggests that patients in GINA 5 subgroup were more susceptible to PAHs exposure. Our data therefore support the avoidance of exposure to high levels of PAHs particularly in GINA step5 patients in whom the resulting clinical benefit would be most felt.

An increased risk of acute asthma exacerbation associated with air pollutants has been previously reported,33–37 with varying severity of exacerbation ranging from easily controlled symptoms to those needing hospitalization. McConnell et al reported that symptoms of bronchitis increased in proportion to the concentration of organic carbon (OC), and particular matter 2.5 (PM2.5), and the levels of gaseous NO2 and O3 in asthmatic children.33 A study in Singapore observed that severe acute exacerbation with emergency department visit was associated with air pollutant level particularly sulfur dioxide (SO2) and the numbers of total suspended particles (TSP) in asthmatic children.34 Furthermore, ambient air pollution was associated with hospital admission for asthmatic patients who are less than 65 years old in Seattle, US.38 In this study area, Taipei City, Yang et al indicated that the risk of hospital admissions for asthma increased when ambient air pollutant (including SO2, NO2, CO and O3) concentrations were higher.21 However, there is no literature on the link between ambient PAHs concentrations and exacerbation frequency of different severities. We demonstrated that severe acute exacerbation was an independent variable that was correlated with acute exacerbation frequency. Besides, patients in GINA 5 subgroup with severe acute exacerbation were more susceptible to ambient PAHs.

Due to the heavy vehicular traffic and the poor dispersion of atmospheric pollutants, relatively high concentrations of atmospheric PAHs are usually found in urban areas.39 The possible mechanisms underlying the induction of exacerbations by PAHs which are considered as outdoor pollutants remain unclear. PAHs may impair the airway epithelium,40 activate inflammatory factors from the airway epithelium,41 that could contribute to the pathogenesis of the acute exacerbation.42 In addition, epithelium dysfunction was observed in severe asthma of GINA step5 and resulted in release of cytokines, such as IL-25, IL-33, thymic stromal lymphopoietin (TSLP) and IL-17A, from an injured epithelium. These cytokines could contribute to eosinophilic airway inflammation and bronchial hyperreactivity.43,44 Exposure to PAHs, such as benzo[a]pyrene, may activate aryl hydrocarbon receptor (AhR) in epithelial cells leading to an enhancement in the production of epithelium-derived cytokines that could contribute to an increase in the rate of severe exacerbations.45,46 Therefore, different severity of acute exacerbation may present with varying degrees of damaged airway epithelium, that may underlie the differential susceptibility to the toxicity of PAHs.

There are limitations in our study. First, the socioeconomic status has been reported to be associated with air pollution on the health effects.47,48 In this study, we did not evaluate the relationship among the annual concentration of PAHs and the acute exacerbation frequency under different socioeconomic status. Future studies to explore the possibility of confounders of the air pollution-socioeconomic status association will be performed. Secondly, we evaluated the effects of PAHs exposure cumulatively but not in a time-stratified case-crossover design. Otherwise, limited by the retrospective nature of our data, we did not identify the exact timing of the episode of acute exacerbation in each patient. We could not report the short-term or seasonal effects of PAHs exposure. Thirdly, outdoor pollutants almost always occur as a mixture. Several outdoor pollutants, such as ozone, nitrogen dioxide, sulfur dioxide, have been associated with asthma exacerbation in the short-term exposure. We did not adjust these components in this study. Therefore, there were no comparative results of outdoor pollutants other than PAHs associated with acute exacerbation. Finally, our study did not examine the link between the inflammatory factors and the PAHs influencing the acute asthma exacerbation. It would therefore be interesting to evaluate the biological and molecular mechanisms of PAHs’ on acute exacerbations at the different levels of severity of asthma.

Conclusion

We found a significant correlation between the annual exacerbation frequency and the annual exposure of polycyclic aromatic hydrocarbons in asthmatic patients. This association was more prominent in the more severe patients with severe acute exacerbations. Control of environmental air pollution level to reduce the frequency of exacerbations will benefit particularly the more severe asthma patient.